Table I.
Binding capacities to HLA-DR and HLA-DP4 molecules of overlapping peptides from LAGE-1
| HLA II Alleles | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptides | HLA-DR B1*0101 |
HLA-DR B1*0301 |
HLA-DR B1*0401 |
HLA-DR B1*0701 |
HLA-DR B1*1101 |
HLA-DR B1*1301 |
HLA-DR B1*1501 |
HLA-DR B3*0101 |
HLA-DR B4*0101 |
HLA-DR B5*0101 |
HLA-DP B1*0401 |
HLA-DP B1*0402 |
| Frequency | 17.7 | 20.6 | 10.9 | 26 | 17.6 | 11.6 | 15.4 | 17.6 | 15.2 | 48.2 | 64 | 20.8 |
| LAGE-169–86 | 20,833 | >255 | >4,578 | >12,703 | 105 | >188 | >3,577 | >10,128 | >1,699 | >18,360 | >7,296 | >5,828 |
| LAGE-176–93 | 171 | >255 | 158 | 1,936 | 63 | >188 | 322 | >10,128 | 224 | 6 | >7,296 | >5,828 |
| LAGE-183–100 | 37 | >255 | 16 | 1 | 17 | 3 | 98 | >10,128 | 27 | 181 | 326 | 260 |
| LAGE-190–107 | 9 | >255 | 393 | 37 | 5,701 | >188 | 35 | 3,693 | >1,699 | 977 | 3,266 | 251 |
| LAGE-197–114 | 215 | 50 | 112 | 51 | 1 | 1 | 2 | 2,384 | 12 | 661 | 130 | 23 |
| LAGE-1104–121 | 1 | 102 | 11 | 43 | 32 | 2 | 0.3 | >10,128 | 20 | 3 | >7,296 | >5,828 |
| LAGE-1111–128 | 13,680 | >255 | 9 | 4,472 | 5,292 | >188 | 100 | >10,128 | 181 | 9,454 | >7,296 | >5,828 |
| LAGE-1b118–135 | 58 | 1 | 30 | 1 | 6 | 2 | 3 | 4 | >1,699 | 17 | 43 | 23 |
| LAGE-1b125–142 | 205 | 2 | 100 | 31 | 26 | 2 | >3,577 | >10,128 | >1,699 | 28 | >7,296 | 88 |
| LAGE-1b132–149 | 183 | 19 | 84 | 112 | 47 | 145 | 1,805 | >10,128 | 297 | 0.4 | >7,296 | 215 |
| LAGE-1b139–156 | 4,516 | >255 | >4,578 | 253 | 1,570 | >188 | 26 | >10,128 | 1,534 | 120 | >7,296 | >5,828 |
| LAGE-1b146–163 | 1,389 | >255 | 1,633 | 393 | 1,167 | >188 | 2 | >10,128 | 1,085 | 68 | >7,296 | 833 |
| LAGE-1b153–170 | 19,118 | >255 | >4,578 | >12,703 | >8,367 | >188 | >3,577 | >10,128 | >1,699 | 4,183 | >7,296 | >5,828 |
| LAGE-1b160–177 | 16,667 | >255 | >4,578 | >12,703 | 970 | >188 | >3,577 | >10,128 | >1,699 | 4,610 | >7,296 | >5,828 |
| LAGE-1b167–184 | >39,260 | >255 | >4,578 | >12,703 | >8,367 | >188 | >3,577 | >10,128 | >1,699 | >18,360 | >7,296 | >5,828 |
| LAGE-1b181–198 | >39,260 | >255 | >4,578 | >12,703 | 3 | >188 | 2,375 | >10,128 | >1,699 | >18,360 | >7,296 | >5,828 |
| LAGE-1b188–210 | 3 | >255 | 3 | 15 | 5 | >188 | 260 | >10,128 | >1,699 | 0.3 | 16 | 6 |
Peptides encompassing the sequences of LAGE-1a (P69–P134) and LAGE-1b (P69–P210), which do not overlap with NY-ESO-1, were submitted to binding assays specific for HLA-DR and HLA-DP4 molecules. Reference peptides were used to validate each assay. These peptides are the nonbiotinylated forms of the biotinylated peptides used in the assay and correspond to very good binders. Data are expressed as relative activity (ratio of the IC50 of the peptides to the IC50 of the reference peptide) and are the means of three experiments. Good binders have a relative activity <100 and are in boldface type.